Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

43

Revenue 2017

Perjeta

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Perjeta was produced by Roche.

Ocrevus helps Roche shrug off biosimilars in 2018

Ocrevus helps Roche shrug off biosimilars in 2018 All told, new products accounted for 90% of Roche’s sales growth in 2018, with another big boost provided by the company’s breast cancer drug Perjeta (pertuzumab), up 27% to

Roche preps new Kadcyla filings after phase 3 trial win

Roche preps new Kadcyla filings after phase 3 trial win Neoadjuvant therapy is given with the intention of achieving a cure for patients with early-stage cancer, and Herceptin and follow-up HER2 drug Perjeta (pertuzumab) have been approved for this ... With Herceptin and follow-up Perjeta (pertuzumab) already

Ocrevus surge keeps Roche smiling in Q3

Ocrevus surge keeps Roche smiling in Q3 However, the performance of Ocrevus and other drugs such as HER2 breast cancer therapy Perjeta (pertuzumab) and lung cancer therapy Alecensa (alectinib) – plus a strong showing in Asia-Pacific markets led

Daiichi-Sankyo takes rival to Roche’s Kadcyla into phase 3

Daiichi-Sankyo takes rival to Roche’s Kadcyla into phase 3 mate Perjeta (pertuzumab).

Daily Brief: Biosimilar Herceptin can't make Perjeta cost effective and more

Daily Brief: Biosimilar Herceptin can't make Perjeta cost effective and more Herceptin biosimilars can’t make Perjeta cost effective, says NICE. NICE has once again rejected Roche’s HER2-positive breast cancer drug Perjeta for treating patients after surgery in those who ... NICE already recommends Perjeta with trastuzumab

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...
PANDAS/PANS Awareness: A parent’s story
To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Iskra Reic
Leading AstraZeneca’s return to growth in Europe
PME talks to Iskra Reic, the company’s head of Europe and Canada...

Infographics